Condition: Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma · Sponsor: Olgun Elicin
COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC). The study investigates whether a risk-adapted, compartmentalized radiotherapy strategy can safely reduce the treatment volume, and thus the side effects, without increasing the risk of tumor recurrence. Eligible patients are those with surgically treated cancers of the oral cavity, oropharynx, larynx, or hypopharynx who have a standard indication for postoperative radiotherapy. The primary outcome is the rate of recurrence in anatomical compartments that would normally be irradiated but are intentionally omitted in this study. COMPORT aims to generate high-level evidence to support a more personalized and less toxic standard of care in postoperative head and neck cancer management.
This description comes directly from the study's public registry record.
Olgun Elicin, Prof. Dr. med. · +41 31 632 26 32 · Olgun.Elicin@insel.ch
Daniel H Schanne, Dr. med. · +41 31 632 26 32 · daniel.schanne@insel.ch
Always discuss trial participation with your own doctor first.
| University Hospital of Basel | Basel, Switzerland | Recruiting |
| Inselspital, Bern University Hospital | Bern, Switzerland | Recruiting |
| University Hospital of Zurich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07058805